

Is Nebulized Ensifentrine Effective and Safe Compared With Placebo for the Treatment of COPD in Chinese Participants?

STUDY DESIGN

Multicenter, randomized, double-anonymized, placebo-controlled trial in COPD randomized to:


Ensifentrine vs **Placebo**

Outcomes

1. ↑ FEV₁
2. quality of life, symptoms, exacerbations

RESULTS

Ensifentrine significantly ↑ FEV₁ compared with placebo
(110 mL; 95% CI, 69-151 mL)



525 patients
45.9% on maintenance therapy

Compared with placebo, **ensifentrine** also:

- ↑ Respiratory surveys scores
- ↓ Rate of exacerbations
- ↑ Time to first exacerbation

Adverse events similar between 2 groups

In this study, ensifentrine was shown to significantly improve lung function and showed efficacy benefits in symptoms, quality of life improvement, and exacerbation reduction in Chinese individuals with COPD.